The DOI matches its Crossref record.
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma
Open accessAbstract
BACKGROUND: The goal of the current study was to evaluate the efficacy and toxicity of capecitabine in patients with nonresectable hepatobiliary carcinoma. METHODS: The authors performed a retrospective analysis of all patients with hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), or gallbladder carcinoma (GBC) who were ever treated with oral capecitabine. The medical records of 116 patients with hepatobiliary carcinoma who were treated at The University of Texas M. D. Anderson Cancer Center (Houston, TX) between July 1998 and March 1999 were reviewed. RESULTS: A total of 63 patients were treated with capecitabine (37 with HCC, 18 with CCA, 8 with GBC). Capecitabine 1000 mg/m 2 was administered twice daily for 14 days. Treatment was repeated every 21 days. Each patient received 1–15 treatment cycles. Nine patients (14%)—11% of patients with HCC, 6% of patients with CCA, and 50% of patients with GBC—had either a complete response (CR) or a partial response. A CR was radiologically confirmed in one patient with HCC and in two patients with GBC. The median survival times were 10.1 months (95% confidence interval [CI], 4.5–15.7 months) for patients with HCC, 8.1 months (95% CI, 7.4–8.9 months) for patients with CCA, and 9.9 months (95% CI, 4.4–15.4 months) for patients with GBC. The most common toxicity was hand‐foot syndrome (37%). Grade 3 thrombocytopenia occurred in 8% of patients with HCC. No other significant toxicities were observed. For all patients, response to treatment was positively correlated with survival and decline in tumor markers. CONCLUSIONS: Capecitabine was found to be safe for patients with hepatobiliary carcinoma, including those with cirrhosis. The antitumor activity of single‐agent capecitabine was most pronounced in patients with GBC, was modest in patients with HCC, and was poor in patients with CCA. Cancer 2004. © 2004 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Omata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026
Goals and targets for personalized therapy for HCC
Couri, T., & Pillai, A. (2019) · Hepatology International · doi:10.1007/s12072-018-9919-1 · Cited by 530
Ben-Josef, E., Guthrie, K. A., El-Khoueiry, A. B., Corless, C. L., Zalupski, M. M., Lowy, A. M., Thomas, C. R., Alberts, S. R., Dawson, L. A., Micetich, K. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.2219 · Cited by 420
Korean Liver Cancer Association, K., & National Cancer Center, N. (2019) · Gut and Liver · doi:10.5009/gnl19024 · Cited by 391
Ben-Josef, E., Normolle, D., Ensminger, W. D., Walker, S., Tatro, D., Ten Haken, R. K., Knol, J., Dawson, L. A., Pan, C., & Lawrence, T. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5354 · Cited by 355
Metadata
- Authors
- Patt, Y. Z., Hassan, M. M., Aguayo, A., Nooka, A. K., Lozano, R. D., Curley, S. A., Vauthey, J., Ellis, L. M., Schnirer, I. I., Wolff, R. A., Charnsangavej, C., & Brown, T. D.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2004-06-28
- Volume
- 101
- Issue
- 3
- Pages
- 578-586
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1970545762
- Cited by
- 203
- References
- 0
- FWCI
- 7.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. https://app.cochat.ai/papers/10.1002/cncr.20368
- The paper
- Patt, Y. Z., Hassan, M. M., Aguayo, A., Nooka, A. K., Lozano, R. D., Curley, S. A., Vauthey, J., Ellis, L. M., Schnirer, I. I., Wolff, R. A., Charnsangavej, C., & Brown, T. D. (2004). Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer. https://doi.org/10.1002/cncr.20368
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.